“Gilead Sciences said on Friday [5/22/26] that its experimental drug for a rare and deadly ​liver infection that had no approved treatment has won U.S. approval.

The U.S. Food and Drug Administration approved the drug, Hepcludex, to treat chronic hepatitis delta virus, or HDV, a liver ​disease that affects only people already infected with hepatitis B and ​can lead to scarring, cancer, organ failure and death…

The approval was based on a late-stage trial, in which ​about 48% of patients who received the treatment showed a meaningful improvement after 48 weeks, ‌compared ⁠with 2% of those whose treatment was delayed. The virus became undetectable in patients the longer they remained on Hepcludex, the trial showed.”

From Reuters.